Showing 161-180 of 258 for: EBMG evidence summaries > Pharmacotherapeutics 
- Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease
EBMG evidence summaries, 2-Mar-2009
Ipratropium bromide appears to be slightly more effective than short-acting beta-agonists in improving lung function and quality of life, and in decreasing the need for oral steroids.
- Lamotrigine versus carbamazepine monotherapy for epilepsy
EBMG evidence summaries, 7-Sep-2006
Lamotrigine monotherapy may be inferior to carbamazepine for seizure control in epilepsy but has improved tolerability.
- Laxatives for the management of constipation in palliative care patients
EBMG evidence summaries, 15-Feb-2011
Subcutaneous methylnaltrexone may be effective in inducing laxation in palliative care patients with opioid-induced constipation and where conventional laxatives have failed, but the safety of this product is not fully evaluated.
- Leflunomide for rheumatoid arthritis
EBMG evidence summaries, 8-Dec-2009
Leflunomide improves clinical outcomes and delay radiologic progression in rheumatoid arthritis. Its efficacy and adverse events are comparable to sulfasalazine (SSZ) and methotrexate (MTX).
- Lithium for schizophrenia
EBMG evidence summaries, 9-Aug-2007
Lithium appears not to be effective on its own for schizophrenia, and the possible benefit of lithium augmentation of antipsychotics is inconclusive.
- Long acting versus short acting beta-agonists in asthma
EBMG evidence summaries, 15-Jun-2006
Long-acting inhaled beta-agonists have better physiological and clinical outcomes than short-acting beta-agonists in regular treatment of asthma but their long-term safety raises concerns.
- Long-acting beta-2 agonists for poorly reversible chronic obstructive pulmonary disease
EBMG evidence summaries, 19-Aug-2008
Salmeterol appears to produce a modest increase in lung function and a reduction in exacerbations in patients with poorly reversible chronic obstructive pulmonary disease. Effects on health related quality of life or on reduction of symptoms are inconclus
- Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma
EBMG evidence summaries, 25-Apr-2006
For adults using moderate to high maintenance doses of inhaled corticosteroid (ICS) for asthma, the addition of a long acting beta agonist has an ICS-sparing effect.
- Long-acting beta2-agonists in addition to inhaled corticosteroids in chronic asthma
EBMG evidence summaries, 27-Jul-2010
In adults with asthma who remain symptomatic on inhaled corticosteroids, the addition of a long-acting beta-2 agonist reduces the rate of exacerbations, improves lung function and symptoms and reduces the use of rescue medication, and may not increase ser
- Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma
EBMG evidence summaries, 20-Jun-2011
In asthmatic adults inadequately controlled on low doses of inhaled steroids, the addition of long-acting beta-2 agonists is superior to anti-leukotrienes for preventing exacerbations requiring systemic steroids, and for improving lung function, symptoms,
- Low dosage tricyclic antidepressants for depression
EBMG evidence summaries, 19-Feb-2004
In the treatment of depression, tricyclic antidepressants in the range between 75–100 mg/day and possibly below this range are more effective than placebo. They appear to have similar efficacy as standard dosage tricyclics but result in fewer dropouts due
- Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes
EBMG evidence summaries, 17-Aug-2007
Low molecular weight heparins and unfractionated heparin are both effective in preventing death but LMWH caused fewer complications.
- Low-molecular weight heparins in pregnancy
EBMG evidence summaries, 7-Aug-2003
The number of adverse events with low-molecular weight heparin (LMWH) during pregnancy may be small, but there are no RCTs comparing LMWH with unfractionated heparin.
- Low-molecular weight heparins in the management of acute coronary syndromes
EBMG evidence summaries, 20-Mar-2003
Low-molecular weight heparins are superior to placebo and unfractionated heparin in reducing ischaemic events or death in acute unstable angina or non-Q-wave myocardial infarction.
- Low-molecular-weight heparins (LMWH) versus unfractionated heparin for venous thromboembolism
EBMG evidence summaries, 14-Oct-2010
LMWH is more effective and safer than unfractionated heparin for the initial treatment of venous thromboembolism. LMWH significantly reduces the occurrence of major haemorrhage during initial treatment and overall mortality at follow up.
- Low-molecular-weight heparins and heparinoids in acute ischemic stroke
EBMG evidence summaries, 5-Feb-2003
Low-molecular-weight heparins and heparinoids reduce venous thromboembolic events in patients with acute ischaemic stroke. However, because of adverse effects, they cannot be recommended for patients with stroke.
- Low-molecular-weight heparins vs. standard heparin for acute ischaemic stroke
EBMG evidence summaries, 27-May-2009
Low molecular weight heparins, when started within 24–48 h of ischaemic stroke, are associated with a reduced risk of venous thromboembolism and no increased risk of bleeding compared with unfractionated heparin use.
- Macrolides for chronic asthma
EBMG evidence summaries, 29-Nov-2006
Macrolides may be beneficial for asthma symptoms in some subgroups of patients, but have no sustained effect on lung function.
- Magnesium sulphate and other anticonvulsants for women with pre-eclampsia
EBMG evidence summaries, 16-Nov-2010
In pre-eclampsia, magnesium sulphate is effective in reducing the risk of eclampsia, and probably reduces the risk of maternal death. It does not improve outcome for the baby, in the short term.
- Maintenance treatment with antipsychotic drugs for schizophrenia
EBMG evidence summaries, 20-Jul-2012
Antipsychotic medication as a maintenance treatment is effective in preventing relapses in schizophrenia.
